In this episode, Albert Rizzo, MD, interviews Geoffrey Chupp, MD, on his team’s research titled "Bronchial Thermoplasty in Patients with Severe Asthma at 5 years: Post-FDA Approval Clinical Trial Evaluating...
This COVID-19 roundup includes coverage of the FDA’s simpler vaccination schedule and authorization of new treatment, decline in pediatric asthma diagnoses during pandemic, and a new treatment combination...
Sublingual allergen immunotherapy has been examined as an alternative treatment option in recent years for individuals with allergic asthma. Is this a treatment option you utilize when managing patients...
The most common type of asthma is allergic asthma, with about 60% of asthma cases caused by allergies. Sean P. Duffy, MD, answers questions about the diagnosis and management of allergic asthma, as well as...
In this video, Elliot Israel, MD, speaks about his team's research titled "A Randomized, Open-Label, Pragmatic Study to Assess Reliever-Triggered Inhaled Corticosteroid in African American/Black and...
Following a multicenter study, the FDA approved the combination of albuterol and budesonide—an inhaled corticosteroid—for the treatment of asthma in adults.
In this podcast, Sumita Khatri, MD, MS, and Teal Hallstrand, MD, MPH, speak about a new clinical practice guideline on fractional exhaled nitric oxide (FeNO) to help guide asthma treatment, including...
Researchers determine which pretreatment biomarkers effectively predict whether the use of omalizumab is useful for patients with severe allergic asthma.
Researchers aimed to investigate the possibility of differentiating between eosinophil subsets in the induced sputum of patients with allergic asthma and to ascertain the distribution of these subsets in...
